eTheRNA
eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.
Total raised
€73M
€73,000,000
Funding rounds
2
Investors
7
distinct backers
Active since
2020-06
latest 2022-08
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood35
base rate 48% for Series B
- ▼ Overdue vs cohort gap
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 13y since founding
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-29 | Series B | €39M | FundPlus,Grand Pharma,LSP,Novalis LifeSciences,Omega Funds,PMV+1 more | View deal → |
| 2020-06-18 | Series B | €34M | — | View deal → |
Related news
- eTheRNA Raises €39M in Series B2 Financingfinsmes.com · 2022-08
- labiotech.eu
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Imec€2.5BBelgium · Deeptech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Kpler€1.0BBelgium · Software